America’s Prescription Drug Pricing Dilemma: Time For Xevant’s Transparency and Action
By Brandon Newman, CEO of Xevant The rising costs of prescription drugs in the United States are becoming unattainable for most Americans. Countless patients are left with no other option but to go without essential medications, which can be life or death. It’s time for real change, beginning with reshaping the convoluted pricing system. The […]
The High Cost of Prescription Drugs in the US: A Barrier To Medication Adherence
By Sahily Paoline, Chief Clinical Officer at Xevant
The prices of prescription drugs in the United States have become a significant obstacle for many individuals seeking access to essential medications. The Office of the Assistant Secretary for Planning and Evaluation shares that the average price increase for drugs from 2016 to 2022 was 31.6%.
The burden of high drug costs often leads to individuals avoiding filling their prescriptions or adhering to prescribed treatment plans, resulting in non-adherence and potentially detrimental health consequences. This article examines the reasons behind this issue, explores potential solutions, and provides advice for readers facing financial difficulties due to drug costs.
Is Upskilling the Key To Employee Retention?
By Megan Foster, Director of People Operations at Xevant
The pandemic fundamentally scared companies. For the first time in a number of years, companies were scrambling to hold onto staff and watching a growing wave of vacancies erode any capacity for production, even after forced separation was no longer required. Some corporations even went so far as to continue to pay employees during their time off in order to prevent them from becoming available on the market and getting hired by a competitor.
For years, compensation was the most reliable and easiest motivation to hold onto valued employees. However, as new generations, such as millennials and even younger, started joining the workforce, much more than compensation started to be considered in order to retain valuable skilled employees.
PBM Transparency Legislation Expected To Be Brought By Congress
Transparency is what PBMs need to be thinking about, Brandon Newman, founder and CEO of Xevant, a data analytics company. “We have to show we’re not hiding behind something, we’re not trying to keep something from our clients or the market,” he said. “And that leads us to the conversation about value.”
Can AI Solve the Adderall Shortage?
By Sahily Paoline, Chief Clinical Officer at Xevant
As children around the country head back to school, the nationwide Adderall shortage is a growing issue for those with ADHD; it is currently estimated that six million children suffer from ADHD in the USA this year. The shortage of this drug has a prominent impact on the future generations of our country, as those without the medication will have impacts on their ability to learn and retain information, attend class, and their overall academic performance.
